92 results about "Pet imaging" patented technology

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

The present application provides a preparation method for a liquid composition comprising Compound I and its use in myocardial perfusion PET imaging. The method comprising the following steps: purifying a crude product comprising the compound I by using high-performance liquid chromatography, wherein a mobile phase used in the high-performance liquid chromatography purification step comprises ethanol and water. By optimizing process parameters and technological process, the method of the present application can be applied to large-scale activity production and meet automation needs. An obtained myocardial perfusion PET imaging agent of this application has high radiochemical purity, high activity concentration, good product stability, and high and stable yield or productivity.

The present invention provides a radiolabeled compound targeting cannabinoid receptor type 2 labeled with the radionuclide 18F. The present invention also provides a process for the preparation of said compound and its use as a positron emission tomography (PET) imaging agent.

The application belongs to the technical field of biological medicine, and discloses a synthesis method of aryl F-18 labeled sulfuryl chloride and application of the aryl F-18 labeled sulfuryl chloride in amine compound labeling. The method takes thiophenol derivative as a labeling precursor, obtains F-18 labeled thiophenol intermediate through photocatalytic aryl F-18 fluorination reaction, and then obtains aryl F-18 labeled sulfuryl chloride through N-chlorosuccinimide oxidation chlorination. The obtained aryl F-18 labeled sulfuryl chloride (4-[ 18 F] fluorobenzenesulfonyl chloride) can occur sulfurylization reaction with various amine compounds at room temperature, and the radiochemical conversion rate is as high as 98%. The application is successfully applied to novel synthesis of AMPA receptor PET imaging agent[ 18 F]2 (the conversion rate is 96%, which is much higher than 13% reported in the literature). The application has the advantages of mild reaction condition, high conversion rate and wide substrate application range, and provides an efficient method for innovative preparation of F-18 labeled PET probes.

A compound or pharmaceutically acceptable salt thereof has at least one bis-phosphonate or bisphosphonate ester group, and a positron emitting radionuclide Po. The positron emitting radionuclide Po is attached to the at least one bisphosphonate or bisphosphonate ester group. The compound may be useful in a method of diagnosis of amyloidosis, such as cardiac amyloidosis.

The application discloses a polypeptide PET molecular probe for targeting breast cancer and a preparation method and application thereof. The polypeptide PET molecular probe for targeting breast cancer is obtained by labeling an AR polypeptide modified by a bifunctional chelating agent with a positron emitting radionuclide, and has the advantages of simple synthesis, small molecular weight, high specificity, no immunogenicity and good biological safety. In addition, the polypeptide PET molecular probe has high radiochemical performance and in-vivo and in-vitro stability, can better realize breast cancer targeted PET imaging compared with current commonly used imaging agents, can be used for preparing an imaging agent for breast cancer diagnosis, and is helpful for clinical diagnosis of breast cancer.

A method for determining a convolution kernel for an iterative statistical algorithm based on a continuous-to-continuous data model. The method is used for image reconstruction from radiation measurements obtained in emission tomography, specifically in a Time-of-Flight Positron Emission Tomography (TOF PET) scanner. The presented method is a non-list-mode solution that reduces the computational complexity of the reconstruction problem, improves the resolution of reconstructed images, reduces the radiation dose absorbed by patients during TOF PET examinations, and / or shortens the measurement acquisition time without significantly compromising the quality of the diagnostic images. Notably, the quality of the functional images remains at the same level. These improvements are achieved by designing the convolution kernel to account for the statistical properties of the measurement signals registered during the TOF PET scanner's acquisition process.

According to the GLP1R targeted radioactive probe, the preparation method and the application, the GLP1R targeted radioactive probe can be specifically combined with GLP1R, has the good in-vivo biological metabolism property, does not cause blood glucose reduction after being injected and is a potential glucagon-like peptide-1 receptor PET imaging probe. The GLP1R targeted radioactive probe is [68Ga] Ga-NOTA-1D32, [68Ga] Ga-NOTA-1D36, or [68Ga] Ga-NOTA-1D39, and the GLP1R targeted radioactive probe is a GLP1R targeted radioactive probe, or a GLP1R targeted radioactive probe, or a GLP1R targeted radioactive probe.

The application discloses a method for constructing fluorine-containing compounds by decarboxylation of alkyl carboxylic acid catalyzed by ketone compounds. The method uses alkyl carboxylic acid with a structure as shown in formula as a reaction raw material, and performs reaction under the joint action of ketone compounds, fluorine-containing reagents and alkali to obtain fluorides shown in formula (1) and formula (2), wherein R 1 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 2 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl; R 3 are respectively and independently selected from hydrogen, a heterocyclic ring, substituted or unsubstituted aryl, and substituted or unsubstituted hydrocarbyl. The reaction method has the advantages of low cost, mild conditions, high reaction efficiency, high yield and high selectivity, and the like. The ketone compounds are used to replace traditional metal catalysts, which can not only provide a fluorine-containing compound library with various structures for candidate drug screening, but also can be applied to positron emission tomography imaging.

The present application relates to the field of biological medicine, and provide a kind of targeting PSMA dimer compound and its derivative and application, the structure general formula of the dimer compound is as shown in formula (I).The dimer compound and its derivative of the present application have very high affinity and targeting to PSMA, after being labeled with suitable radionuclide, can be used as nuclear medicine molecular probe, to realize early diagnosis, staging and treatment of prostate cancer, 68 Ga]diPSMA-1-DOTA showed good tumor uptake in PET imaging of tumor mice.Therefore, this kind of radioactive complex has good clinical application prospect in tumor imaging targeting PSMA (especially PET imaging), and lays an important foundation for the radiotherapy application of [ 177 Lu]diPSMA-1-DOTA and [ 225 Ac]diPSMA-1-DOTA.

The application discloses a PET imaging correction method fusing a large model prior. The method comprises the following steps: acquiring a to-be-corrected PET image and structured text information, and then using a trained conditional flow matching network model architecture fusing a large model prior to obtain a corrected PET image, wherein the conditional flow matching network model architecture fusing the large model prior comprises a large model, a multi-core fusion module, a conditional flow matching model and an affine transformation module, the large model is used to generate a text description of the to-be-corrected PET image in accordance with anatomical logic, the multi-core fusion module is used to weight and fuse the PET image and the text information to obtain enhanced image features with text prior information, the conditional flow matching model is used to obtain a predicted vector field through a conditional flow matching process based on the enhanced image features, and then a corrected PET image is obtained through gradual flow according to the predicted vector field. The application can effectively solve the problems of residual artifacts and structural distortion existing in the traditional PET correction method.

This invention discloses a PET image reconstruction method and system based on manifold prior constraints, belonging to the field of medical image reconstruction and intelligent information processing technology. It acquires historical PET image datasets and PET measurement data from positron emission tomography (PET), constructs a data consistency term based on a Poisson statistical model, and introduces the image manifold prior into the PET image reconstruction optimization model. The optimization model is solved using an alternating iterative approach based on variable splitting, including data consistency updates, manifold projection updates, and dual variable updates. Finally, the reconstructed PET image is output. This invention organically combines the PET imaging physical model with data-driven prior generation, which is beneficial for improving reconstructed image quality, suppressing noise, and preserving structural details in low-dose PET imaging scenarios.

Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.

The application discloses a kind of based on image block Transform network's dual-tracer PET imaging method, the method will mixed tracer concentration map be divided into equal size image block, all image block is flattened and then extracted feature input Transform network, with corresponding single tracer concentration map as true value label, train network to learn the corresponding relationship between the two, separate the concentration map of single tracer from dual-tracer concentration map.The network model used in the application uses attention mechanism completely, does not depend on recurrent neural network or convolutional neural network, can be processed in parallel and expand the receptive field of image in network learning process, pay more attention to time information and spatial information in a larger range, obtain more accurate separation result.Experiments prove that the generalization of the application is less affected by the spatial position misregistration of images in the training data set during the test process compared with other deep learning methods, and has high robustness.

The present disclosure relates to a system for imaging. The system may include a supporting assembly and a detector assembly. The supporting assembly may include a detection region to accommodate a subject. The detector assembly may surround the detection region. The detector assembly may be configured to detect radiation rays emitted from the subject located within the detection region. The detector assembly may include a plurality of detector rings. Each detector ring may include a scintillator array and a plurality of photosensors. The plurality of detector rings may be arranged on the supporting assembly in an axial direction of the supporting assembly to form an axial field of view (FOV) having a length no less than 0.75 meters.

Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.

The invention relates to the technical field of medical imaging diagnosis, in particular to a CSF1 receptor-targeted PET (positron emission tomography) developer as well as a labeled precursor, a preparation method and application thereof. The structural formula of a labeled precursor compound pre-FPPA of the PET imaging agent for targeting the CSF1 receptor provided by the invention is as shown in a formula I, and the structural formula of the PET imaging agent 18F-FPPA for targeting the CSF1 receptor provided by the invention is as shown in a formula II. According to the invention, a 6-Aryl group is used as a pharmacophore, the structure of the 6-Aryl group is completely consistent with that of an original drug in a CSF1 receptor antagonist (DFFPA), only isotope difference exists, and the consistency of stability, affinity and specificity of the 6-Aryl group can be ensured to the greatest extent. The prepared PET imaging agent 18F-FPPA has good stability and pharmacokinetic characteristics, and a foundation is laid for scientific research and clinical application of an F-18 labeled targeted CSF1 receptor PET imaging agent.

The application discloses a PET imaging device, a PET device and a treatment system for multi-field particle therapy. The PET imaging device comprises: an identification unit configured to identify one or more time intervals of each field according to a time distribution feature of acquired single-event data, each time interval corresponding to a particle beam delivery state; a coincidence processing unit configured to perform coincidence processing on the single-event data to generate coincidence event data; and a reconstruction unit configured to perform image reconstruction on the coincidence event data in the identified time intervals of each field to obtain a corresponding reconstructed image of each field. Through intelligent identification of the time distribution feature and a partition reconstruction strategy, the application solves the problem of serious overlap of PET signals in a multi-field delivery mode, and realizes accurate extraction of independent dose distribution of each field and image reconstruction.

A radioactive medical isotope labeled rare-earth doped nanomaterial, a PET imaging diagnosis and treatment agent, a preparation method therefor and an application thereof. The radioactive medical isotope labeled rare-earth doped nanomaterial comprises an inner core. The structural general formula of the inner core is MxTyFx+4y:Ln / R, wherein M is an alkali metal element, and T is a transition metal element and selected from one or more of Ti, Zr and / or Hf; 1 ≤ x ≤ 7, 1 ≤ y ≤ 6; Ln is a rare earth element and stable isotope; R is a radioactive medical isotope having radioactivity and selected from one or more of 90Y, 177Lu, 153Sm, 223Ra, 111In and, 89Zr. The radioactive medical isotope labeled rare-earth ion doped nanomaterial can realize deep tissue penetration high-resolution rare earth fluorescence and global PET multimodal medical images, and is a multifunctional inorganic nano rare earth fluorescent PET imaging agent capable of being effectively degraded and removed in an organism.

The invention provides a radiopharmaceutical and application thereof, and relates to the technical field of nuclear medicine, the radiopharmaceutical provided by the invention can be used as an integrin alpha4beta7 imaging agent, and imaging diagnosis can be carried out on focuses of diseases (such as inflammatory bowel diseases or tumor diseases) related to positive expression of integrin alpha4beta7 by utilizing a PET imaging technology of nuclear medicine. A chelating part in the integrin alpha4beta7 radiopharmaceutical can be replaced by NOTA chelating agents, NODAGA chelating agents, DOTAGA chelating agents, THP chelating agents and TRAP chelating agents, and the integrin alpha4beta7 radiopharmaceutical can be used for labeling < 68 > Ga metal nuclides, < 61 > Cu metal nuclides, < 64 > Cu metal nuclides and < 177 > Lu metal nuclides, so that PET imaging and nuclide treatment of various nuclides are further realized.

This application relates to a peptide targeting LGR5, a PET molecular probe, its preparation method, and its application. The peptide is any one of the following: (1) its amino acid sequence is YLASRVH; (2) a derived peptide formed by substituting one or more amino acids into the amino acid sequence shown in (1), wherein the derived peptide has the same or substantially the same function as the peptide with the sequence shown in (1); (3) a derived peptide after chemical or genetic modification of the peptide in (1) or (2). The PET molecular probe targeting LGR5 includes a peptide targeting LGR5, a chelating agent, and a radionuclide. The probe of the present invention has good stability, high affinity and specificity for LGR5, and can sensitively monitor the LGR5 expression level at the tumor site; it is also rapidly metabolized in vivo and provides fast imaging. In LGR5-positive tumor models, it can reach the tumor site in a short time and obtain high-contrast PET imaging effects.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.

The application discloses a scattering correction method, a PET imaging method, a device, equipment and a storage medium. The scattering correction method comprises the following steps: obtaining TOF-PET data and an attenuation image of a target object during scanning; obtaining a back projection image of TOF information based on the TOF-PET data; obtaining a scattering estimation of TOF-PET imaging based on the back projection image and the attenuation image; and performing scattering correction on the TOF-PET data based on the scattering estimation of TOF-PET imaging. The application solves the technical problem of long time consumption of scattering correction in TOF-PET imaging in the prior art.

The application discloses a PET tracer targeting carbonic anhydrase IX (CA IX) and a preparation method and application thereof. 68 The tracer is prepared from a DOTA-bis-sulfonamide precursor compound and GaCl3 reaction. The tracer has high hydrophilicity, excellent stability in vitro and in vivo, low uptake of non-target organs and is mainly excreted through the kidney. Micro-PET / CT imaging shows that the tumor uptake is linearly correlated with the CA IX protein expression level measured by immunohistochemistry. Acute toxicity experiments show that the tracer has good biological safety. The application further provides a radiopharmaceutical composition containing the tracer and application of the tracer in preparation of a PET imaging agent for diagnosing CA IX positive tumors. The tracer has the advantages of high labeling efficiency, low background interference, accurate quantification and potential integration of diagnosis and treatment, and is suitable for precise molecular imaging of CA IX high expression tumors such as clear cell renal cell carcinoma and colorectal cancer.

Disclosed are substituted heterocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of formula (I) as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The disclosure further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

The invention discloses a method for diagnosing and treating AD (Alzheimer's disease) by recognizing olfactory disorder through PET (Polyethylene Terephthalate). The method comprises the following steps: (1) observing olfactory and cognitive behavioral changes of AD mice, and evaluating olfactory and cognitive function conditions of the 3 * Tg mice by carrying out behavioral experiments on the 12-month-old 3 * Tg mice; and (2) quantifying A beta in the intracranial olfactory related area of the AD mouse through PET imaging, performing A beta-PET imaging on a 12-month-old 3xTg mouse, reconstructing a PET image through a PET / CT scanner, performing SUV quantification on the intracranial olfactory related area, and observing the deposition condition of the A beta in the olfactory related area. And (3) observing A beta and tau phosphorylation expression and distribution conditions of AD mice in pathology, observing A beta expression and distribution conditions in brains of 12-month-old 3xTg mice through immunofluorescence, dividing olfaction-related regions by referring to an Allen mouse brain map, observing expression conditions of A beta in the olfaction-related regions, and calculating average fluorescence intensity of each region for semi-quantitative analysis.

The present invention relates to a novel MAO-B inhibitor compound and, more specifically, provides a novel compound which selectively binds to MAO-B over MAO-A and tau through modification of conventional THK5351, thereby having a remarkably improved ability to inhibit MAO-B. According to the present invention, the compound has excellent MAO-B-specific binding and MAO-B inhibitory effects, and thus can be used for the diagnosis or treatment of neurological diseases overexpressing MAO-B, and can be used as a tracer or contrast agent in PET imaging.